Morsink Nino Chiron, Nijsen Johannes Frank Wilhelmus, Grinwis Guillaume Cornelis Maria, Hesselink Jan Willem, Kirpensteijn Jolle, van Nimwegen Sebastiaan Alexander
Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
Front Vet Sci. 2022 Nov 1;9:1015248. doi: 10.3389/fvets.2022.1015248. eCollection 2022.
Minimally invasive microbrachytherapy is in development to treat solid tumors by intratumoral injection of (radioactive) holmium-166 (Ho) microspheres (MS). A high local dose can be administered with minimal damage to surrounding tissue because of the short soft tissue penetration depth of Ho beta radiation. We aimed to prospectively evaluate the safety and efficacy of Ho microbrachytherapy in client-owned canine patients with soft tissue sarcomas (STS).
We included seven dogs with STS not suitable for local excision due to tumor size and/or location. HoMS were suspended in a carrier fluid and multiple needle-injections were performed in predetermined tumor segments to maximize tumor coverage. Tumor response was evaluated using 3D caliper and CT measurements. Follow-up further included monitoring for potential side effects and registration of subsequent treatments and survival, until at least two years after treatment.
Delivered radioactive doses ranged from 70 to 969 Gy resulting in a mean tumor volume reduction of 49.0 ± 21.3% after 33 ± 25 days. Treatment-related side effects consisted of local necrosis ( = 1) and ulceration of the skin covering the tumor ( = 1), which resolved with basic wound care, and surgical excision of residual tumor, respectively. Residual tumor was surgically resected in six patients after 22-93 days. After a mean follow-up of 1,005 days, four patients were alive, two patients were euthanized because of unrelated causes, and one patient was euthanized because of disease progression after the owner(s) declined subsequent surgical treatment.
Ho microbrachytherapy was a safe and effective neoadjuvant treatment option for canine patients with STS.
微创微近距离放射治疗正在研发中，通过瘤内注射（放射性）钬 - 166（Ho）微球（MS）来治疗实体瘤。由于Hoβ射线在软组织中的穿透深度较短，因此可以在对周围组织损伤最小的情况下给予高局部剂量。我们旨在前瞻性评估Ho微近距离放射治疗在患有软组织肉瘤（STS）的宠物犬患者中的安全性和有效性。
我们纳入了7只因肿瘤大小和/或位置而不适合局部切除的患有STS的犬。将HoMS悬浮在载液中，并在预定的肿瘤节段进行多次针注射，以最大限度地覆盖肿瘤。使用三维卡尺和CT测量评估肿瘤反应。随访还包括监测潜在的副作用以及记录后续治疗和生存情况，直至治疗后至少两年。
给予的放射剂量范围为70至969 Gy，在33±25天后平均肿瘤体积减少49.0±21.3％。与治疗相关的副作用包括局部坏死（n = 1）和覆盖肿瘤的皮肤溃疡（n = 1），分别通过基本伤口护理和手术切除残留肿瘤得到解决。6例患者在22 - 93天后手术切除残留肿瘤。平均随访1005天后，4例患者存活，2例患者因无关原因实施安乐死，1例患者在主人拒绝后续手术治疗后因疾病进展实施安乐死。
Ho微近距离放射治疗是患有STS的犬患者的一种安全有效的新辅助治疗选择。
